Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.

Authors :: Schrogie JJ
Source :: American heart journal [Am Heart J] 1999 May; Vol. 137 (5), pp. S126-8.
Publication Year :: 1999

Subjects :: Abciximab
Antibodies, Monoclonal economics
Cardiovascular Diseases economics
Cost-Benefit Analysis
Drug Costs
Economics, Pharmaceutical
Humans
Immunoglobulin Fab Fragments economics
Pharmacy and Therapeutics Committee
Platelet Aggregation Inhibitors economics
United States
Antibodies, Monoclonal therapeutic use
Cardiovascular Diseases drug therapy
Formularies as Topic
Immunoglobulin Fab Fragments therapeutic use
Platelet Aggregation Inhibitors therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors

Full Text Access

Tools